The Tisch Cancer Institute

Clinical Trials Office

The primary mission of the Cancer Clinical Trials Office (CCTO) is to assist The Tisch Cancer Institute (TCI) investigators in the development, conduct, and reporting of innovative clinical research in an efficient, compliant, and scientifically sound manner. The CCTO is composed of regulatory, financial, clinical, study management, compliance, and data management personnel that support investigators and provide uniformity and consistency in clinical research. The CCTO provides management and oversight functions for coordinating, facilitating, and reporting on the cancer clinical trials that complement the Protocol Review and Monitoring System (PRMS). There is a Quality Assurance Program (QAP) responsible for centralized education and training services, subject central registration, auditing, and the development of policy, which supports the TCI Data and Safety Monitoring Committee (DSMC) to ensure data integrity, while promoting subject safety. 

Oversight of clinical research is intended to ensure that TCI investigators conduct high-quality science in a responsible manner, with minimal risk to patients.                                          

Matthew Galsky, MD
Medical Director, CCTO and Novel Therapeutics Program

Ajai Chari, MD
Associate Medical Director, CCTO

Paula Klein, MD
Associate Medical Director, CCTO

Max Sung, MD 
Chair, Data Safety & Monitoring Committee

The CCTO is organized by divisions that provide distinct, well-integrated services under unified leadership reporting to Rosemarie Gagliardi, Associate Dean of Clinical Research Operations. Skilled personnel are available to assist Investigators by providing administrative, regulatory, finance management, study coordination, quality assurance, educational support and data management and reporting.

Rosemarie Gagliardi
Associate Dean, Clinical Research Operations

Jennifer Cocco
Director, Research Information Systems 

Richa Upadhyay
Associate Director, Clinical Trials Conduct          

Margarita Gilyadova
Assistant Director, Clinical Trials Support Services

Nancy Lowe
Clinical Research Manager, Study Start-Up

Ariel Hosey
Clinical Trials Analyst

Robert Hutter
Administrative Assistant, CCTO

Clinical research nurses and coordinators have regular assignments with investigators by disease-specific research teams to build expertise in particular areas of oncology.

Richa Upadhyay
Solid Tumors and Lymphoma 

Christine Woo
Bone Marrow Transplant

Erin Demakos
Malignant Hematology- Myelodysplastic Syndromes (MDS)              

Alicia Orellana
Malignant Hematology- Myeloproliferative Diseases (MPD)  

Lisa La
Malignant Hematology-Multiple Myeloma

Simona Podgrabinska
Immunotherapy/Vaccine

Lynda N. Rath
Radiation Oncology

The Novel Therapeutics Program at the Tisch Cancer Institute was established to facilitate the conduct of early phase cancer clinical trials including first-in-human and biomarker focused proof-of-concept-studies, representing a multi‐disciplinary collaborative effort to maximize both the efficiency and scientific value of early phase clinical investigation while simultaneously bringing the most cutting‐edge therapies to our cancer patients.

To date we have conducted more than sixty Phase 1 clinical trials in Solid Tumors and Malignant Hematology.

Available Resources dedicated to the Novel Therapeutics Program include:

  • Fast Track “One Stop Shop”
  • Expert Clinical Investigators with dedicated disease‐specific research teams
  • Experience with Industry, Cooperative Groups, Investigator Initiated and Consortium Trials
  • Network of Basic and Translational Scientists in Cancer Mechanisms and Immunology

For Institutional Resources supporting the Novel Therapeutics Program: Flyer

For more information please contact us directly at 212-824-7288 or e-mail:

Medical Director: Matthew Galsky, MD
Immunotherapy: Nina Bhardwaj, MD, PhD
Immunotherapy: Joshua Brody, MD
Operations: Rosemarie Gagliardi
Regulatory Coordinator: Catherine Raimond

The Cancer Clinical Trials Office currently supports three prestigious research consortia:

MAGIC-Mount Sinai Acute GVHD International Consortium: Composed of 10 major stem cell transplant centers in the United States and Europe who are collaborating to use this new scoring system to test new treatments for acute GVHD.

Contact: Rachel Young

MPD-RC- Myeloproliferative Diseases Research Consortium: An international, multi-institutional consortium set up to coordinate, facilitate, and perform basic and clinical research investigating the genetic and cellular mechanisms of the Philadelphia Chromosome (Ph) negative myeloproliferative neoplasms (MPNs). 

Contact: Alicia Orellana           

MyTRO- Myeloma Translational Research Organization: A unique clinical research organization connecting sites and myeloma patients with promising drugs through clinical trials. MyTRO offers an efficient solution from providing multiple research sites in the tri-state area.

Contact: Schantel Williams